Breathomics—exhaled volatile organic compound analysis to detect hepatic encephalopathy : a pilot study by Arasaradnam, Ramesh P. et al.
  
 
 
 
warwick.ac.uk/lib-publications 
 
 
 
 
 
Original citation: 
Arasaradnam, Ramesh P., McFarlane, M., Ling, K., Wurie, S., O’Connell, N., Nwokolo, Chuka 
U., Bardhan, Karna Dev, Skinner, J., Savage, Richard S. and Covington, James A.. (2016) 
Breathomics—exhaled volatile organic compound analysis to detect hepatic encephalopathy 
: a pilot study. Journal of Breath Research, 10 (1). 016012. 016012. 
 
Permanent WRAP URL: 
http://wrap.warwick.ac.uk/78450 
 
Copyright and reuse: 
The Warwick Research Archive Portal (WRAP) makes this work of researchers of the 
University of Warwick available open access under the following conditions. 
 
This article is made available under the Creative Commons Attribution 4.0 International 
license (CC BY 4.0) and may be reused according to the conditions of the license.  For more 
details see: http://creativecommons.org/licenses/by/4.0/   
 
A note on versions: 
The version presented in WRAP is the published version, or, version of record, and may be 
cited as it appears here. 
 
For more information, please contact the WRAP Team at: wrap@warwick.ac.uk 
 
© 2016 IOP Publishing Ltd
Abbreviations
AUROC Area under receiver operator curve
BAD Bile acid diarrhoea
GCMS Gas chromatography and mass 
spectrometry
HCC Hepatocellular carcinoma
HE Hepatic encephalopathy
IBD Inflammatory bowel disease
MELD Model for end stage liver disease
uvFAIMS Ultra-violet field asymmetric ion mobility 
spectroscopy
VOCs Volatile organic compounds
1. Introduction
Hepatic encephalopathy (HE) is a progressive but 
reversible neuropsychiatric condition and is the hallmark 
of decompensated liver disease [1]. The clinical spectrum 
of HE is broad with varying degrees of symptoms and 
effects on intellectual, cognitive and motor function. 
The distinction of the various classes of HE are currently 
made clinically via the use of the West Haven criteria 
(see table 1). Clinical presentation ranges from no 
impairment of cognitive function (Grade 0), to minimal 
HE (MHE) which has imperceptible clinical symptoms, 
requiring cognitive testing to elucidate, to minor 
cognitive impairment (Grade I), to the more apparent 
confusion and coma (Grade II–IV). West Haven criteria 
are commonly utilized but are subject to inter-observer 
variability [2]. A recent attempt to clarify the diagnosis 
by the International Society for Hepatic Encephalopathy 
and Nitrogen Metabolism (ISHEN) guidelines led to the 
re-classifying of Minimal and Grade I HE into ‘covert 
HE’ (CHE), with Grades II to IV as ‘overt HE’ (OHE), 
but scoring still based on the West Haven criteria [2].
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Abstract
The current diagnostic challenge with diagnosing hepatic encephalopathy (HE) is identifying 
those with minimal HE as opposed to the more clinically apparent covert/overt HE. Rifaximin, 
is an effective therapy but earlier identification and treatment of HE could prevent liver disease 
progression and hospitalization. Our pilot study aimed to analyse breath samples of patients with 
different HE grades, and controls, using a portable electronic (e) nose.
42 patients were enrolled; 22 with HE and 20 controls. Bedside breath samples were captured and 
analysed using an uvFAIMS machine (portable e-nose). West Haven criteria applied and MELD 
scores calculated.
We classify HE patients from controls with a sensitivity and specificity of 0.88 (0.73–0.95) and 0.68 
(0.51–0.81) respectively, AUROC 0.84 (0.75–0.93). Minimal HE was distinguishable from covert/
overt HE with sensitivity of 0.79 and specificity of 0.5, AUROC 0.71 (0.57–0.84).
This pilot study has highlighted the potential of breathomics to identify VOCs signatures in HE 
patients for diagnostic purposes. Importantly this was performed utilizing a non-invasive, portable 
bedside device and holds potential for future early HE diagnosis.
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The development of HE is associated with a poorer 
prognosis, even accounting for a patients Model for 
End Stage Liver Disease (MELD) score [3]. The preva-
lence of minimal HE is reported between 30%–84% 
in patients with liver cirrhosis, with profound effects 
on daily functioning and nearly 50% of minimal HE 
patients may be unfit to maintain employment [1]. 
Therefore earlier detection of minimal HE and the pre-
vention of overt HE are clearly of vital importance.
Current regimes for treatment and secondary pre-
vention of various grades of HE include non-absorba-
ble disaccharides (e.g. lactulose) and non-absorbable 
antibiotics e.g. Rifaxamin [1]. Non-absorbable disac-
charides are fermented in the colon resulting in the 
formation of lactic and acetic acid which converts 
ammonia into ammonium which is not systemically 
absorbed and excreted in the stool. These non-absorba-
ble disaccharides are currently recommended as 1st line 
therapy for overt HE [4]. There is increasing evidence 
to support their use in the treatment of minimal HE, 
with significant reduction in abnormal psychological 
testing, blood ammonia levels and progression to overt 
HE, including a meta-analysis of five studies [1].
Rifaxamin, meanwhile, acts by inhibiting bacterial 
RNA/protein synthesis, thus modulating their activity 
and reducing intestinal ammonia and toxin formation 
[1]. It has been demonstrated to be a superior treat-
ment option than lactulose alone to overt HE [5], and to 
work best when combined with lactulose to treat overt 
HE [6]. It has since been demonstrated to improve neu-
ropsychometric functioning, reduce ammonia levels 
and improve Health Related Quality of Life (HRQoL) 
scores and improve driving function [7, 8].
While these treatments have been demonstrated to 
improve symptoms and daily functioning of patients 
with minimal HE and overt HE, most will only receive 
treatments after they have presented with overt HE. 
Earlier detection of these clinical states may allow 
treatment to be started earlier and improve the long 
terms clinical outcomes for these patients. Thus the 
clinical challenge is to detect those with minimal HE 
using non-invasive and reliable tools.
The detection of volatile organic compounds 
(VOCs) has been a rapidly expanding area of research 
in recent years. The study of the potential use of VOC 
patterns in bodily secretions (breath, urine and faeces) 
as non-invasive biomarkers to help identifying vari-
ous disease states in multiple body systems has shown 
considerable promise [9–19]. The mechanism by 
which VOCs are generated is the subject of on-going 
research. Their generation within the body can be the 
result of metabolic derangement, toxin or teratogen 
exposure and finally microbiological process [20, 21]. 
Within the GI tract their production represents the 
results of fermentation of dietary non-starch polysac-
charides and thus the complex interaction of diet, gut 
epithelial cells, human gut microflora and invading 
pathogens [22–24]. These fermentation products can 
exist in the gaseous phase and are present in exhaled 
air, sweat, urine and faeces [25]. Their presence in 
bodily secretions from sites other than the GI tract 
(sweat, exhaled air and urine) is possible due to the 
altered gut permeability afforded in certain disease 
states. This allows the transfer of the VOCs into cir-
culating blood, and from there they can either; pass 
into the lungs via the right ventricle (volatiles which 
are highly diffusible will then preferentially cross the 
alveolar membrane and exit in exhaled breath) or 
the urine (via filtration after circulatory delivery to 
the kidneys) [21, 25].
There is now increasing evidence that gut micro-
biota play a major role in the pathogenesis of liver dis-
ease ranging from non-alcoholic fatty liver disease to 
cirrhosis and hepatocellular carcinoma (HCC) [26]. We 
believe that VOCs represent a patient specific bio-signa-
ture, which is affected by a variety of factors including 
Table 1. West Haven classification.
Stage Definition
0 Lack of detectable changes in personality or behaviour.
Minimal changes in memory, concentration, intellectual function, and coordination.
Asterixis are absent.
1 Trivial lack of awareness.
Shortened attention span.
Impaired addition or subtraction.
Hypersomnia, insomnia, or inversion of sleep pattern.
Euphoria, depression, or irritability.
Mild confusion.
Slowing of ability to perform mental tasks.
Asterixis can be detected.
2 Lethargy or apathy. Minimal disorientation. Inappropriate behaviour. Slurred speech. Obvious asterixis.  
Drowsiness, lethargy, gross deficits in ability to perform mental tasks, obvious personality changes, inappropriate 
behaviour, and intermittent disorientation, usually regarding time.
3 Somnolent but can be aroused, unable to perform mental tasks, gross disorientation about time and place, marked 
confusion, amnesia, occasional fits of rage, present but incomprehensible speech.
4 Coma with or without response to painful stimuli.
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host microbiome, disease state and environmental fac-
tors such as diet.
There are a number of approaches to measure VOCs 
in breath. Most early studies employed GCMS (gas 
chromatography mass spectrometry), through a sepa-
rate capture and pre-concentration approach (usually a 
tedlar bag or metal pipe followed by subsequent capture 
on tenax tube and desorption into the GCMS system) 
[27]. The large number of steps together with limited 
chemical information captured and the expense of the 
equipment makes this approach of limited clinical use. 
More recently, SIFT-MS (selective ion flow tube-mass 
spectrometer) has been the method of choice for breath 
analysis [28]. It is highly sensitive and selective, but has 
a unit cost even greater than GCMS and is significantly 
more bulky. Both of these approaches require special-
ized facilities, services and trained staff to operate. 
There have also been a number of studies employing 
electronic (e) noses. These instruments can be made 
portable, relatively low-cost and use air as the carrier 
[9]. However, they are limited to sensor drift, humid-
ity dependence and low sensitivity. More recently, 
FAIMS (field asymmetric ion mobility spectrometer) 
has shown promise in the medical domain, using the 
movement of molecules in high electric fields. Such 
instruments can work at room temperature and pres-
sure, use air as the carrier gas and have reduced drift due 
to measuring physical properties of molecules (instead 
of chemical in an electronic nose) [14]. Usually, these 
instruments require a Ni-63 radioactive source, which 
requires special licenses in many countries. However, 
the uvFAIMS system (deployed in this work) removes 
this need, making it more applicable to such studies. We 
believe that this is the first medical work reported using 
this instrument.
The aim of this study is to determine whether HE 
could be distinguished from healthy controls by analy-
sis of exhaled VOCs (breathomics). We also sought to 
determine whether it could be have potential to distin-
guish covert from overt HE.
2. Materials and methods
2.1. Subjects
A total of 42 patients were recruited for this pilot 
study; 22 patients with HE (13 covert and 9 with overt 
HE as well as 20 healthy controls without clinical or 
biochemical evidence of liver disease. Healthy controls 
were chosen to confirm that the breath profiles of those 
with liver disease are distinct from the healthy. All the 
liver patients had disease secondary to alcohol injury. 
Severity of disease and grading was recorded according 
to West Haven and the updated ISHEN criteria (table 1) 
as well as MELD scores. Patients’ demography and 
diets were recorded. Patients with type 2 diabetes or 
other gastrointestinal conditions (inflammatory bowel 
disease, coeliac disease and cancer) were excluded from 
the study. The demographics of the subjects are shown 
in table 2.
2.2. Specimen collection
Morning breath samples were taken from both patients 
and controls after a period of at least a 2 hour fast and 
absence of cigarette smoking. The specimens were 
collected using a 3 litre Tedlar® bag (Thames Restek, 
UK) which had a ¼ inch OD nozzle tube and threaded 
valve for sample capture. A custom made breath capture 
device was constructed to allow sampling. The breath 
capture device allows patients to breathe naturally 
through a mouth piece into the attached Tedlar® bag. 
The device comprises of a filter, to ensure controlled 
environmental standards for sampling, to which is 
connected to a 2 way valve. The two way valve allows the 
patient to inhale clean air (which first passes through 
the filter) and then exhale into the tedlar bag. These 
valves also had custom made PTFE adaptors attached to 
allow for connection to disposable mouthpieces, whilst 
the other adaptors connect to an additional three way 
tap between the exhaled breath path and the Tedlar bag. 
This tap is then attached to the breath bag via disposable 
tubing and allows for the isolation of end-tidal breath 
in the bags, which has higher VOC content. All samples 
were obtained from patients directly and placed in a 
freezer (−20 °C) as soon as possible. The samples were 
then shipped to the University of Warwick with a total 
of one hour to reach room temperature before analysis 
(including the transport time). Once defrosted the 
sample bags were attached to the FAIMS via the custom 
unit as described in the next section. All samples were 
tested on the same day as capture.
2.3. Analysis
Analysis was undertaken using an ultra-violet Field 
Asymmetric Ion Mobility Spectroscopy (uvFAIMS, 
Lonestar, Owlstone UK). This system achieves 
separation of chemical components on the basis of 
differences in molecular mobilities in a high electric 
field. FAIMS allows gas molecules to be separated 
and analysed at atmospheric pressure and room 
temperature. Once the sample is ionized, the resulting 
ions are passed between two metal plates and then an 
asynchronous high voltage waveform is applied to 
these plates, subjecting the ionized molecules to high 
electric fields. The difference in movement of these ions 
within this high electric field can be measured, thus 
Table 2. HE patient demographics.
Demographic
Liver patients 
(n  =  22)
Controls 
(n  =  20)
Sex (Male: Female) 15 : 7 6 : 14
Mean Age (Range; SD) 55 (30–80; 15) 31 (23–54; 10)
HE grade  
(Covert & Overt)
13 : 9 NA
Mean MELD score 
(Range; SD)
13 (6.4– 19; 3.7) NA
HE prophylaxis (Y/N)  20 : 2 NA
current smokers (Y/N) 3 : 19 1 : 19
Mean BMI (Range; SD) 26 (16–40; 6.3) 24 (18–3; 3.2)
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resulting in a separation of the complex mixture. The 
field dispersion (ion mobility) is then tracked to form a 
characteristic plume.
The Lonestar was modified with a custom set up 
designed specifically for breath sampling. This custom 
made unit comprises an inlet port for the Tedlar® 
bags, compressed air running through a mass-flow 
controller (MFC) and an external pump on the instru-
ment exhaust. The use of a MFC allowed for greater 
control of the air : sample ratio to optimize the analy-
sis conditions. The flow rate of the sample was set by 
controlling the difference between the pump (set to 
1.8 l min−1) and the compressed air line (1.5 l min−1) 
this results in a vacuum and the sample inlet then 
draws 300 ml min−1 of the breath sample into the 
machine for analysis. Each sample was run to collect 
2 matrices of data, using approximately 2.3 l of sample.
2.4. Statistical methods
The extracted data was then analysed using a previously 
developed analysis pipeline based on a 2D wavelet 
transform and threshold to remove background noise. 
This was followed by feature selection to identify key 
variables (using a Wilcoxon rank-sum test applied 
separately to each feature), with the resultant feature set 
used to separately train four classifiers (sparse logistic 
regression, Random Forest, Support Vector Machine 
and Gaussian Process). Sensitivity, specificity, and 
Area Under Receiver Operator Curve (AUROC) were 
calculated in leave-one-out cross validation. Sparse 
logistic regression gave the best overall performance, so 
we report those results unless otherwise stated. We note 
that the study of multiple classifiers can be important as 
our experience with a range of FAIMS data sets shows 
that different classifiers can be best-performing in each 
case.
2.5. Ethics
Ethical approval was obtained from the Warwickshire 
Research and Development Department and 
Warwickshire Ethics committee (09/H1211/38). 
Written informed consent was obtained from all 
patients who participated in the study.
3. Results
There was a range of severity of liver disease as reflected 
by the MELD score. There were 13 patients with covert 
HE and 9 patients with overt HE. The demographics of 
the subjects are covered in table 2 and the medications of 
the liver patients and controls in table 3.
Classification of those with HE and controls was 
achieved with sensitivity and specificity of 0.88 (95% 
Confidence Interval (CI): 0.73–0.95) and 0.68 (95% CI: 
0.51–0.81) respectively, and AUROC of 0.84 (95% CI: 
0.75–0.93)—figure 1(a). Further analysis to separate cov-
ert HE from overt HE revealed a sensitivity of 0.79 (95% 
CI: 0.49–0.95) and specificity of 0.50 (95% CI: 0.37–0.63), 
AUROC 0.71 (95% CI: 0.57–0.84)—figure 1(b).
There was no statistically significant differences 
between differing HE grades (as per older West Haven 
criteria) in this pilot study, AUROC 0.61 (95% CI: 
0.43–0.79). However, this may be due in part to the even 
smaller sample size.
4. Discussion
This pilot study provides initial evidence that breath 
VOC analysis has potential application as a diagnostic 
aid in distinguishing HE of all grades from healthy 
controls subjects. It may also have potential as an aid 
to distinguish covert HE from overt HE. This finding 
was through the detection of a unique gas phase bio-
odorant fingerprint found in the breath of patients with 
HE, detected here by uv FAIMS analysis. It also expands 
on previous work into the non-invasive detection of 
many luminal GI diseases by VOC detection and more 
recently the non-invasive detection of NAFLD and 
NASH/NASH-C [9, 11–15].
Exhaled VOCs analysis performed reasonably well 
as a clinical tool when distinguishing HE patients from 
controls, suggesting a discernible VOC profile for the 
condition. The sensitivity and specificity for distin-
guishing HE from the healthy controls were 0.88 and 
0.68, AUROC 0.84 (95% CI: 0.75–0.93). Within HE 
patients, covert HE could be distinguished from overt 
HE with a sensitivity of 0.79 and specificity of 0.50, 
AUROC 0.71 (95% CI: 0.57–0.84).
Table 3. Medications of HE patients and controls.
Medications
Liver patients 
(n  =  22)
Controls 
(n  =  20)
Gastrointestinal:
Thiamine/Vitamin B  
Co-strong/Folate
14
Proton Pump Inhibitors 9
Lactulose 5
Pabrinex 2
Chlordiazepoxide 2
Spironolactone/Frusemide 4
Carvedilolol/Beta Blocker 1
Antiemetics 1
Ursodeoxycholic acid 1
Cardiovascular:
Antihypertensives 2 2
Statins 2
Aspirin 1
Neurological:
Selective Serotonin  
Reuptake Inhibitors
5
Antipsychotics 2
Anti-convulsants 1
Opiods 2
Respiratory:
Inhalers 2 2
Endocrine:
Thyroxine 0 1
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uvFAIMS is highly sensitive, portable instrument 
that detects both VOCs and gasses and is able to detect 
chemicals down to the parts per trillion (ppt) level 
(depending on their proton affinity). The instrument 
is sensitive to ammonia, but due to the range of molecu-
lar mobilities used in the analysis ammonia may only 
be one of a number of chemicals that play an important 
role. However, the role of ammonia testing in the diag-
nosis of HE has long been in question. It has value in 
the management of acute liver failure, but is not useful 
for the evaluation or screening of HE in patients with 
CLD as it does not confirm or exclude HE, and levels do 
not correlate with the degree of encephalopathy [29]. 
This technology does not allow for specific quantifica-
tion of the chemicals that separate the groups nor is it 
necessary. It highlights rather the potential for real time 
separation of VOC profiles utilizing non-invasive tech-
nology (which is portable; all analysis was carried out 
at the bedside) to aid in the earlier detection of covert 
HE, and could help prevent reliance on time consum-
ing neuropsychometric testing to identify this clinical 
condition. Consequently Lactulose or Rifaximin treat-
ment could potentially be initiated at an earlier stage to 
hopefully provide better long term outcomes for CLD 
patients complicated by HE.
The non-invasive detection of disease specific vola-
tile organic compounds (VOCs) patterns, detectable 
in urine, breath, sweat and faeces has become a rapidly 
developing field in recent years, termed ‘fermentonom-
ics’. Detection of these gas phase biomarkers (VOCs/
gasses) has increasingly been recognized as non- 
invasive means to positively diagnose patients with a 
wide range of diseases including pulmonary, infectious, 
metabolic and gastrointestinal diseases. Exhaled VOC 
analysis by more conventional GC-MS (gas chroma-
tography and mass spectrometry) technology has been 
demonstrated to aid in the distinction of not just can-
cer from non-cancer patients but also multiple cancer 
subtypes including lung, breast, prostate and colorectal 
cancer [9, 10]. More recently, urinary VOCs have also 
been demonstrated to have potential diagnostic value in 
liver disease, particularly non-alcoholic fatty liver dis-
ease, in the distinction of fatty liver disease from healthy 
controls and also Cirrhotic Non-alcoholic steatohepati-
tis (NASH-C), from non-cirrhotic NASH [15].
Exhaled biomarkers have also been used in liver 
disease for the detection of hepatocellular carcinoma 
and fatty liver disease in humans [16–18]. Recent ani-
mal studies have shown that Electronic-nose technol-
ogy is able to detect acute liver failure in rats with high 
classification accuracy [19]. VOCs are believed to be a 
physiological by- products of colonic fermentation and 
represent the result of the complex interaction between 
the gut epithelial cells, faecal flora, mucosal integrity 
and invading pathogens [12]. This provides supportive 
evidence for the role for gut microbial dysbiosis in the 
pathophysiology of liver disease, which has been sug-
gested in other studies [26, 30, 31].
It should be noted that FAIMS technology, unlike 
technology based around Mass Spectrometry, does not 
allow for specific quantification of the chemicals that 
separate the groups, instead it represents the overall 
‘smell print’ of the VOC cocktail. The value of FAIMS 
is the potential for real time separation of VOC profiles 
utilizing non-invasive technology (which is portable, 
breath analysis can be carried out at the bedside) to aid 
in the detection of HE and the distinction of the various 
grades of HE. This is of great clinical relevance. FAIMS 
is significantly cheaper technology that SIFT-MS, is a 
much smaller unit and does not require any specialized 
infra-structure making it more applicable to a medical 
setting [32].
Although the sample size in this proof of principle 
study is small, the HE patients show good reclassifica-
tion accuracy within the statistical analysis. This sug-
gests a discernible VOC profile for the HE, and part-
icularly covert HE from overt HE. As this was a pilot 
study, we have not controlled for age or sex but previous 
work has not shown differences in VOC profiling based 
on sex, age, or medication differences [11, 13, 33].
Given the small sample size in this pilot study, larger 
validation studies are needed to confirm the reproduc-
ibility of our findings in those with all grades of HE 
and matched controls (liver disease without HE). Thus 
Figure 1. ROC plots for distinguishing (a) HE from controls 
and (b) covert HE from overt HE.
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breathomics in HE does hold potential for rapid, port-
able and non-invasive diagnosis for a condition, which, 
as yet is difficult to diagnose.
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